Mirjana Krkobabić

Ms. Mirjana Krkobabić

Department of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, University of Belgrade, Serbia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Mirjana KrkobabićMirjana Krkobabić
Mirjana Krkobabić
DMDjordje Medarević
Djordje Medarević
Sandra CvijicSandra Cvijic
Sandra Cvijic
BGBranka Grujić
Branka Grujić
SISvetlana Ibrić
Svetlana Ibrić

31 August 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Mirjana KrkobabićMirjana Krkobabić
Mirjana Krkobabić
DMDjordje Medarevic
Djordje Medarevic
NPNikola Pesic
Nikola Pesic
DVDragana Vasiljevic
Dragana Vasiljevic
BIBranka Ivkovic
Branka Ivkovic
Svetlana IbricSvetlana Ibric
Svetlana Ibric
Three-dimensional (3D) printing technologies are based on successive material printing layer-by-layer and are considered suitable for the production of dosage forms customized for a patient’s needs. In this study, tablets of atomoxetine hydrochloride (ATH) have been successfully fabricated by a digital light processing (DLP) 3D printing technology. Initial materials were photoreactive suspensions, composed of poly(ethylene glycol) diacrylate 700 (PEGDA 700), poly(ethylene glycol) 400 (PEG 400), photoinitiator and suspended ATH. The amount of ATH was varied from 10.00 to 25.00% (w/w), and a range of doses from 12.21 to 40.07 mg has been achieved, indicating the possibility of personalized therapy. The rheological characteristics of all photoreactive suspensions were appropriate for the printing process, while the amount of the suspended particles in the photoreactive suspensions had an impact on the 3D printing process, as well as on mechanical and biopharmaceutical characteristics of tablets. Only the formulation with the highest content of ATH had significantly different tensile strength compared to other formulations. All tablets showed sustained drug release during at least the 8h. ATH crystals were observed with polarized light microscopy of photoreactive suspensions and the cross-sections of the tablets, while no interactions between ATH and polymers were detected by FT-IR spectroscopy.

15 December 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DMDjordje Medarevic
Djordje Medarevic
Jelena DjurisJelena Djuris
Jelena Djuris
Mirjana KrkobabićMirjana Krkobabić
Mirjana Krkobabić
Svetlana IbricSvetlana Ibric
Svetlana Ibric
Co-processing is commonly used approach to improve functional characteristics of pharmaceutical excipients to become suitable for tablet production by direct compression. This study aimed to improve tableting characteristics of lactose monohydrate (LMH) by co-processing by fluid-bed melt granulation with addition of hydrophilic (PEG 4000 and poloxamer 188) and lipophilic (glyceryl palmitostearate) meltable binders. In addition to binding purpose, hydrophilic and lipophilic excipients were added to achieve self-lubricating properties of mixture. Co-processed mixtures exhibit superior flow properties compared to pure LMH and comparable or better flowability relative to commercial excipient Ludipress®. Compaction of mixtures co-processed with 20% PEG 4000 and 20% poloxamer 188 resulted in tablets with acceptable tensile strength (>2 MPa) and good lubricating properties (ejection and detachment stress values below 5 MPa) in a wide range of compression pressures. While the best lubricating properties were observed when glyceryl palmitostearate was used as meltable binder, obtained tablets failed to fulfil required mechanical characteristics. Although addition of meltable binder improves interparticle bonding, disintegration time was not prolonged compared to commercial excipient Ludipress®. Co-processed mixtures containing 20% of either PEG 4000 or poloxamer 188 showed superior tabletability and lubricant properties relative to LMH and Ludipress® and can be good candidates for tablet production by direct compression.